Navigation Links
Groundbreaking UK Study Confirms Significant Reduction in Hospital Superbug Pathogens with TRU-D SmartUVC Disinfection Robot
Date:7/18/2013

NOTTINGHAM, England, July 18, 2013 /PRNewswire/ -- A recent study titled "First UK evaluation of an automated ultraviolet-C room decontamination device (TRU-D™)" confirms the effectiveness of TRU-D SmartUVC™ in eliminating common superbugs in health care environments.

The study was conducted by the Department of Clinical Microbiology and Infection Prevention and the Control Department at Nottingham University Hospitals NHS Trust's QMC campus in Nottingham, England, and was published in the Journal of Hospital Infection (N. Mahida, et al., 2013). The research concluded that when delivering a measured and consistent UV-C dose in a cleaned, unoccupied patient room, TRU-D reduced MRSA, MRA and VRE pathogens by 99.99 percent. Additionally, the study complements the ease of use and transporting the device, as well as its rapid disinfection time.

TRU-D was the only device utilized in the study. Short for Total Room Ultraviolet Disinfector, TRU-D – the signature product of Memphis-based Lumalier – is the only portable UV disinfection system on the market that precisely measures reflected UV-C emissions with Sensor360™ to automatically calculate the pathogen-lethal UV dose required for proper and consistent disinfection of health care environments. A proper dose of UV-C light modifies the DNA structure of an infectious cell so it cannot reproduce and therefore cannot colonize and spread.

After a hospital room is cleaned using traditional methods, TRU-D is rolled into the room to "finish the job." Setup is fast and easy and does not require input of room measurements or covering of windows and vents. The machine is turned on from outside the room using a handheld remote. From a single placement near the center of the room, its patented Sensor360™ technology instantly analyzes the unique contents, shape and size of the room, then floods the targeted space (both line-of-site and shadowed spaces) with the proper dose of germicidal energy. TRU-D spends whatever time is necessary (usually 20 to 35 minutes) to confidently eliminate infectious germs from contaminated surfaces before shutting down and audibly notifying the operator that disinfection is complete.    

In this UK study, TRU-D was used in six side-rooms in Nottingham University Hospital NHS Trust's QMC campus' intensive therapy unit, an operating theater and a ward isolation room with an in-suite bathroom. The device was placed in the middle of the room, and contact plates inoculated with clinical strains of MRSA, MRA, VRE and aspergillus were placed on 15 touch surfaces in both direct and indirect (shadowed) line of sight of TRU-D. After one disinfection cycle, the plates were then reapplied to surfaces directly adjacent to the original plate locations. The study specifically notes TRU-D's capability "to significantly reduce key health care nosocomial pathogens (MRSA, VRE, MRA) in the hospital environment," including the operating theatre; and that advantages include the device's simplicity and limited training needed by staff to operate TRU-D.

Studies show that 50 percent or more of hospital surfaces go untouched during terminal room disinfection.  The Centers for Disease Control and Prevention reports that health care-associated infections are tied to an estimated 99,000 deaths in the USA each year and represent an estimated $30 billion a year in medical costs. Recently, the European Centre for Disease Prevention and Control released its first point prevalence survey, which reported that on any given day, about 80,000 patients -- or one in 18 patients -- in European hospitals have acquired at least one health care-associated infection.

"Health care leaders around the world are recognizing the importance of adding automated no-touch disinfection technology to comprehensive manual cleaning routines already in place," said Chuck Dunn, president of Lumalier. "TRU-D is being used in hundreds of hospitals around the U.S. and Canada, and we will continue to expand our science-based market leadership in the UK."

            For information, visit www.TRU-D.com.

 

For more information, contact:

Lauren Hannaford

Obsidian Public Relations

Phone: 901-572-1042

Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE TRU-D LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
2. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
3. Babys life saved with groundbreaking 3D printed device from U-M that restored his breathing
4. Thousands Of Cats With Kidney Disease Sought For Groundbreaking Clinical Trial
5. Premier Cancer Centers Dallas opens up a new world of groundbreaking and life-saving technology
6. Mayor Greg Ballard to Join Roche Diagnostics Leaders at Groundbreaking of New Learning and Development Center
7. Richard Wolf Medical Instruments introduces groundbreaking 5514 Endocam Performance HD
8. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
9. Study Estimates that 4.3 Million Prescriptions for Painkillers Were Diverted to Illicit Use by "Doctor Shoppers"
10. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
11. RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... 2017 partnership with The Jensie Gran Fondo of Marin. For the second year ... with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, ...
(Date:2/23/2017)... ... 23, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Miami Beach to host its Swirl: Miami Wine Tasting Event on March 28, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael ... “Mama June: From Not to Hot,” which will begin airing on February 24, 2017. ... to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO ... the National Institute for Health and Care Excellence (NICE) framework. The ... National Health Service (NHS) to search, order and purchase medical and healthcare-related content ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
Breaking Medicine News(10 mins):